The health and economic burden of rotavirus disease in Belgium

被引：26

作者：

Bilcke, Joke ^{[1
]}

Van Damme, Pierre ^{[1
]}

De Smet, Frank ^{[2
]}

Hanquet, Germaine ^{[3
]}

Van Ranst, Marc ^{[4
]}

Beutels, Philippe ^{[1
,5
]}

机构：

[1] Univ Antwerp CDE, Vaccine & Infect Dis Inst, Ctr Evaluat Vaccinat, Unit Hlth Econ & Modelling Infect Dis, B-2610 Antwerp, Belgium

[2] Natl Alliance Christian Sickness Funds, B-1031 Brussels, Belgium

[3] Sci Inst Publ Hlth, B-1050 Brussels, Belgium

[4] Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Lab Clin & Epidemiol Virol, B-3000 Leuven, Belgium

[5] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia

来源：

EUROPEAN JOURNAL OF PEDIATRICS | 2008年 / 167卷 / 12期

关键词：

Burden; Cost; Rotavirus;

D O I：

10.1007/s00431-008-0684-3

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

For health economic evaluations of rotavirus vaccination, estimates of the health and cost burden of rotavirus are required. Due to differences in health care systems and surveillance organisations, this is difficult to achieve by imputing estimates from one country to others. This study aimed to estimate the burden of rotavirus disease in Belgium. In children younger than 7 years of age, rotavirus is predicted to account annually for about 5,600 hospitalisations (676:100,000 children); 26,800 outpatient, general practitioner and paediatrician visits; and about 44,600 episodes for which no medical care is sought. This burden is estimated to represent direct costs of 7.7 million (sic) and indirect costs of 12.8 million (sic). Rotavirus disease causes a substantial health and economic burden in Belgium.

引用

页码：1409 / 1419

页数：11

共 40 条

[1] Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy Brazilian infants
Araujo, Eliete C.
Clemens, Sue ann C.
Oliveira, Consuelo S.
Justino, Maria Cleonice A.
Rubio, Pilar
Gabbay, Yvone B.
da Silva, Veronilce B.
Mascarenhas, Joana D. P.
Noronha, Vania L.
Clemens, Ralf
Gusmao, Rosa Helena P.
Sanchez, Nervo
Monteiro, Talita Antonia F.
Linhares, Alexandre C.
[J]. JORNAL DE PEDIATRIA, 2007, 83 (03) : 217 - 224
[2] The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium)
Beutels, P
Van Damme, P
Van Casteren,V
Gay, NJ
De Schrijver, K
Meheus, A
[J]. VACCINE, 2002, 20 (29-30) : 3551 - 3559
[3] BEUTELS P, 2006, KCE REPORTS C, V133
[4] BILCKE J, 2007, KCE REPORTS C, V154
[5] Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and "No Medical Care" Disease Impact in Belgium
Bilcke, Joke
Van Damme, Pierre
Beutels, Philippe
[J]. MEDICAL DECISION MAKING, 2009, 29 (01) : 33 - 50
[6] Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life
Block, Stan L.
Vesikari, Timo
Goveia, Michelle G.
Rivers, Stephen B.
Adeyi, Ben A.
Dallas, Michael J.
Bauder, Jeffrey
Boslego, John W.
Heaton, Penny M.
[J]. PEDIATRICS, 2007, 119 (01) : 11 - 18
[7] Briggs A, 2006, DECISION MODELLING H
[8] Rotavirus vaccines - An update
Dennehy, Penelope H.
[J]. VACCINE, 2007, 25 (16) : 3137 - 3141
[9] DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569
[10] Frühwirth M, 2001, PEDIATR INFECT DIS J, V20, P784, DOI 10.1097/00006454-200108000-00013

← 1 2 3 4 →